October 13, 2022
TransCelerate BioPharma Inc., today announced that Janice Chang, currently its Chief Operating Officer, has been appointed as TransCelerate’s new Chief Executive Officer. Janice will assume the role on January 1, 2023. Read more in the press release.
Explore
September 9, 2021
TransCelerate BioPharma Inc. (TransCelerate) announced today that it has commenced development on a reference implementation of a study definitions repository. The study definitions repository is a novel central component aimed at facilitating the exchange of structured study definitions across clinical systems using technical and data standards. For the full press release, please click here.
Explore
June 7, 2021
BioCelerate, a subsidiary of TransCelerate BioPharma Inc. that focuses on identifying and developing pragmatic and tangible solutions to improve efficiencies in nonclinical research, today announced that it has released the first set of its solutions as part of its Public Private Partnership (PPP) with the U.S. Food & Drug Administration’s Center for Drug Evaluation and…
Explore
October 19, 2020
DataCelerate® COVID-19 Module, Modernizing Critical Trial Conduct, Real World Data and Pharmacovigilance Agreements Optimization were all launched to support the continuity of clinical trials. We’ve also elected new Board leaders and added Bayer Pharmaceuticals as our newest member.
Explore
June 17, 2020
TransCelerate BioPharma Inc., a non-profit collaboration comprised of 20 of the largest biopharmaceutical companies, today announced that it is expanding access to COVID-19-related patient-level clinical data sharing via DataCelerate® to non-member companies. In addition, TransCelerate will expand the type of data shared to include data from both the investigational product and control arms of COVID-19 clinical trials.…
Explore
April 15, 2020
TransCelerate BioPharma Inc. announced that it will be utilizing its DataCelerate® platform to share Member Company control arm data from ongoing and planned COVID-19 clinical studies, as well as data from past studies in related diseases or patient populations. For the full press release click here.
Explore
June 10, 2019
Explore
May 23, 2019
TransCelerate announced it has committed to an expansion of its clinical and drug safety portfolio, revealing three new initiatives: the Common Clinical Serious Adverse Events Fields Initiative, the Modernization of Data Analytics for Clinical Development Initiative and the Interpretation of Guidances and Regulations Initiative.
Explore
August 3, 2018
DataCelerateTM Seamlessly Connects Clean, Converted Clinical & Preclinical Information within One Data Lake Solution.
Explore
May 18, 2018
TransCelerate announced the addition of several new initiatives to its expanded portfolio that leverage advancements in automation and analytics and focus on data quality, safety and integrity.
Explore
